Aquestive Therapeutics, INC Form 4 insider transactions

Daniel Barber, President and CEO of Aquestive Therapeutics, Inc., sold 25,000 shares of common stock on July 15, 2026.

Aquestive Therapeutics Director Julie Krop executed a Rule 10b5-1 trading plan, exercising options and selling shares.

Aquestive Therapeutics President and CEO Daniel Barber reported a sale of 25,000 shares of common stock.

Director Timothy E. Morris was granted 50,500 stock options in Aquestive Therapeutics, Inc. as part of a standard equity incentive.

Director Julie Krop was granted 50,500 stock options in Aquestive Therapeutics, Inc. as part of a standard equity compensation plan.

Director Abigail L. Jenkins was granted 50,500 non-qualified stock options in Aquestive Therapeutics, Inc.

Director John Cochran was granted 50,500 stock options in Aquestive Therapeutics, Inc. as part of a standard equity incentive.

Director Gregory B. Brown was granted 50,500 stock options in Aquestive Therapeutics, Inc. as part of a standard equity incentive.

Director Marco Taglietti was granted 50,500 stock options in Aquestive Therapeutics, Inc. as part of a compensation arrangement.

Aquestive Therapeutics reports Sherry Korczynski's transaction involving shares withheld for tax obligations related to Restricted Stock Units.

Thomas A. Zalewski, Chief Legal Officer of Aquestive Therapeutics, Inc., reported a significant acquisition of common stock and stock options.

Aquestive Therapeutics President and CEO Daniel Barber reported a sale of 8,257 shares of common stock on May 15, 2026, at a weighted average price of $4.2889 per share.

Melina Cioffi, SVP of Regulatory Affairs at Aquestive Therapeutics, reported a transaction involving the sale of 1,667 shares of common stock.

Lori J. Braender, Corporate Secretary at Aquestive Therapeutics, reported a transaction involving the withholding of shares to cover tax obligations.

Chief People Officer Peter E. Boyd reported the withholding of 56,778 shares to satisfy tax obligations related to PSU vesting.

Aquestive Therapeutics CEO Daniel Barber reported the withholding of 335,922 shares to satisfy tax obligations related to vested performance stock units.

Aquestive Therapeutics CFO A. Ernest Toth Jr. reported the withholding of 92,652 shares to satisfy tax obligations related to vested performance stock units.

Aquestive Therapeutics COO Cassie Jung reported the withholding of 72,734 shares to satisfy tax obligations upon the vesting of performance stock units.

Corporate Secretary Lori J. Braender disposed of 76,147 shares of Aquestive Therapeutics to satisfy tax obligations related to PSU vesting.

Aquestive Therapeutics CEO Daniel Barber reports the grant of 293,100 Performance Stock Units (PSUs) vesting in March 2028.

Aquestive Therapeutics' Chief People Officer, Peter E. Boyd, was granted 60,000 Performance Stock Units on March 7, 2025, with vesting contingent on performance metrics through March 7, 2028.

Aquestive Therapeutics' Chief Operating Officer, Cassie Jung, was granted 60,000 Performance Stock Units (PSUs) vesting in March 2028, with the filing noting an administrative oversight for the late submission.

Aquestive Therapeutics SVP and CFO, Ernest A. Toth Jr., received 82,500 Performance Stock Units (PSUs) on March 7, 2025, with vesting contingent on performance through March 7, 2028.

Aquestive Therapeutics reports the grant of 67,500 Performance Stock Units to Chief Commercial Officer Sherry Korczynski, with vesting tied to specific stock price performance over three years.

Aquestive Therapeutics Corporate Secretary Lori Braender was granted 82,500 Performance Stock Units (PSUs) vesting in 2028, with the filing late due to administrative oversight.

Aquestive Therapeutics' Chief People Officer, Peter E. Boyd, acquired 20,000 shares of common stock as restricted stock, vesting over three annual installments.

Aquestive Therapeutics SVP of Regulatory Affairs, Melina Cioffi, disposed of 2,083 shares of common stock to cover tax obligations related to RSU vesting.

Aquestive Therapeutics' Chief Development Officer, Matthew W. Davis, was granted 50,000 shares of restricted stock and 50,000 non-qualified stock options.

Aquestive Therapeutics' Chief Operating Officer, Cassie Jung, exercised stock options and sold a portion of her common stock holdings under a pre-arranged 10b5-1 trading plan.

Aquestive Therapeutics' Chief Medical Officer, Carl N. Kraus, sold 20,272 shares of common stock for a weighted average price of $7.00 per share under a pre-arranged 10b5-1 trading plan.